

Errata

During FY 2024, FDA received an inquiry that alerted us to certain discrepancies in our Advisory Committee Vacancies and Public Disclosures Report for past fiscal years. Upon review, FDA determined that some reports included a limited number of inaccurate figures in Table 2, primarily due to data entry and tabulation errors. The revised tables are included below and corrections are marked in red. We have instituted an additional layer of review as a quality control measure and will be exploring additional process improvements for metric reporting.

FY 2016

Table 2 - 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted FY 2016

		Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due to reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
FDA TOTAL		64	1770 1778	91(5%)	638 (36%)	1049	8 (0.76%)	1041	99.24%
Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants <u>Not</u> Issued Waivers
OFFICE OF THE COMMISSIONER		5	111	2 (2%)	28 (25%) 27 (24%)	82	0 (0%)	82	100.00%
Science Board to the Food and Drug Administration	11/18/2015	1	20	0	7	13	0	13	100.00%
Science Board to the Food and Drug Administration	3/1/2016	1	24	1	3	20	0	20	100.00%
Pediatric Advisory Committee	4/12/2016	1	22	0	3	19	0	19	100.00%
Pediatric Advisory Committee	9/14/2016	1	29	1	11 10	18	0	18	100.00%
Risk Communication Advisory Committee(RCAC)	2/16-17/2016	1	16	0	4	12	0	12	100.00%
CENTER FOR BIOLOGICS EVALUATION & RESEARCH		9	175	8 (4%)	38 (22%)	129	1 (0.78%)	128	99.22%
Allergenic Products	1/21/2016	1	12	1	1	10	0	10	100.00%
Blood Products	6/20/2016	0	14	0	4	10	0	10	100.00%
Cellular, Tissue and Gene Therapies//Joint Meeting with Oncologic Drugs	11/18/2015	1	50	2	21	27	0	27	100.00%
Cellular, Tissue and Gene Therapies	2/16/2016	1	13	0	1	12	0	12	100.00%
Cellular Tissue and Gene Therapy Advisory Committee	7/26/2016	1	11	0	2	9	0	9	100.00%
Cellular Tissue and Gene Therapy Advisory Committee	9/7/2016	1	11	0	1	10	0	10	100.00%
Vaccines and Related Biological Products	11/13/2015	1	20	4	3	13	1	12	92.31%

Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due to reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants Not Issued Waivers
CENTER FOR DRUG EVALUATION AND RESEARCH Cont.									
Dermatologic and Ophthalmic Drugs Advisory Committee	7/19/2016	1	50	2	30	18	0	18	100.00%
Drug Safety and Risk Management Advisory Committee	5/3-4/2016	1	55	2	22 23	30	0	30	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	12/14/2015	1	21	2	4	15	0	15	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	5/24/2016	1	34	0	17	17	0	17	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	5/25/2016	1	33	0	16	17	0	17	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	6/28/2016	1	40	2	15	23	1	22	95.65%
Gastrointestinal Drugs Advisory Committee (joint w/ Drug Safety and Risk Management Advisory Committee)	4/7/2016	1	32	1	14	17	0	17	100.00%
Nonprescription Drugs Advisory Committee	4/15/2016	1	38	1	21	16	0	16	100.00%
Oncologic Drugs Advisory Committee Pediatric Oncology Subcommittee	11/19/2015	1	21	4	7	10	0	10	100.00%
Oncologic Drugs Advisory Committee	9/14/2016	1	19	1	4	14	0	14	100.00%
Oncologic Drugs Advisory Committee	4/12/2016	1	20	2	4	14	0	14	100.00%
Pediatric Sub-Committee/ODAC	6/28-29/2016	1	25	0	9	16	4	12	75.00%
Peripheral and Central Nervous System Drugs Advisory Committee	11/24/2015	1	32	0	15	17	0	17	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	4/25/2016	1	17	1	3	13	0	13	100.00%
Pharmaceutical Science and Clinical Pharmacology Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Pharmacy Compounding Advisory Committee	10/27-28/2015	1	24	0	10	14	0	14	100.00%
Pharmacy Compounding Advisory Committee	3/8-9/2016	1	18	0	6	12	0	12	100.00%
Pharmacy Compounding Advisory Committee	6/23/2016	1	17	1	4	12	0	12	100.00%

Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants Not Issued Waivers
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH Cont.									
Ear, Nose, and Throat Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gastroenterology and Urology Devices Panel	2/25-26/2016	1	25	1	10	14	0	14	100.00%
General and Plastic Surgery Devices Panel	9/20-21/2016	1	31	0	15	16	0	16	100.00%
General Hospital and Personal Use Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hematology and Pathology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Immunology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Medical Devices Dispute Resolution Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Microbiology Devices Panel	8/16/2016	1	27	1	9	17	0	17	100.00%
Molecular and Clinical Genetics Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Neurological Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Obstetrics and Gynecology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Ophthalmic Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Orthopedic and Rehabilitation Devices Panel	2/19/2016	1	29	1	14	14	0	14	100.00%
Orthopedic and Rehabilitation Devices Panel	4/20/2016	1	22	0	7	15	0	15	100.00%
Radiologic Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Technical Electronic Safety Standards Advisory Committee Product Radiation	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
National Mammography Quality Assurance Advisory Committee	9/15/2016	1	13	0	2	11	0	11	100.00%
Patient Engagement Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH		1	0 8	0 (0%)	0	8	0 (0%)	8	100.00%
Science Advisory Board to the National Center for Toxicological Research	11/1-2/2015	1	0 8	0	0	8	0	8	100.00%
CENTER FOR TOBACCO PRODUCTS		N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Tobacco Products Scientific Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
* Not including Industry Representatives, Regular FDA Employees, and Guest Speakers									

FY 2018

Table 2 - 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted FY 2018

Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants Not Issued Waivers
FDA TOTAL		55 56	1422 1449	61 (5%) 62 (4%)	490 (32%) 499 (34%)	872 888	12 (1.9%) (1.4%)	860 876	98.62% 98.65%
OFFICE OF THE COMMISSIONER		4	101	0 (0%)	31 (31%)	70	0	70	100.00%
Science Board to the Food and Drug Administration	4/23/2018	1	16	0	1	15	0	15	100.00%
Pediatric Advisory Committee(Joint meeting with Endocrinologic and Metabolic Drugs Advisory Committee)	5/11/2018	1	31	0	11	20	0	20	100.00%
Pediatric Advisory Committee	9/20/2018	1	22	0	8	14	0	14	100.00%
Risk Communication Advisory Committee	3/5-6/2018	1	32	0	11	21	0	21	100.00%
CENTER FOR BIOLOGICS EVALUATION & RESEARCH		9	197	6	58	133	0	133	100.00%
Allergenic Products Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Blood Products Advisory Committee	3/21-22/2018	1	33	4	13	16	0	16	100.00%
Blood Products Advisory Committee	6/22/2018	1	15	0	4	11	0	11	100.00%
Blood Products Advisory Committee	7/18-19/2018	1	29	2	9	18	0	18	100.00%
Blood Products Advisory Committee	11/30-21/1/2017	1	26	0	5	21	0	21	100.00%
Cellular, Tissue and Gene Therapies Advisory Committee	10/12/2017	1	17	0	0	17	0	17	100.00%
Vaccines and Related Biological Products Advisory Committee	10/4/2017	1	17	0	0	17	0	17	100.00%
Vaccines and Related Biological Products Advisory Committee	10/4/2017 11/7/2017	1	44 32	0	4 18	40 14	0	40 14	100.00%
Vaccines and Related Biological Products Advisory Committee	5/17/2018	1	16	0	4	12	0	12	100.00%
Vaccines and Related Biological Products Advisory Committee	3/1/2018	1	15	0	1	14	0	14	100.00%

Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending) *	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants Not Issued Waivers
Center for Drug Evaluation and Research (Cont.)									
Dermatologic and Ophthalmic Drugs Advisory Committee	10/13/17	1	12	0	2	10	0	10	100.00%
Drug Safety and Risk Management Advisory Committee	8/3/2018	1	41	3	19	19	0	19	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	10/18/2017	1	24	1	6	17	0	17	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	5/10/2018	1	25	2	3	20	0	20	100.00%
Gastrointestinal Drugs Advisory Committee	5/3/2018	1	37	1	12	24	0	24	100.00%
Gastrointestinal Drugs Advisory Committee	3/8/2018	1	31	5	10	16	3	13	81.25%
Medical Imaging Drugs Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Nonprescription Drugs Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Oncologic Drugs Advisory Committee	3/7/2018	1	23	0	11	12	0	12	100.00%
Pediatric Sub-Committee/Oncologic Drugs Advisory Committee	6/20/2018	1	20	0	3	17	0	17	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	4/19/2018	1	23	2	8	13	0	13	100.00%
Pharmaceutical Science and Clinical Pharmacology Advisory Committee	9/20/2018	1	14	0	3	11	0	11	100.00%
Pharmacy Compounding Advisory Committee	11/20-21/2017	1	16	0	0	16	0	16	100.00%
Pharmacy Compounding Advisory Committee	9/12/2018	1	16	0	0	16	1	16 15	93.75%
Psychopharmacologic Drugs Advisory Committee	10/31/2017	1	33	0	14	19	0	19	100.00%
Psychopharmacologic Drugs Advisory Committee	11/1/2017	1	33	0	33 12	21	0	21	100.00%
Psychopharmacologic Drugs Advisory Committee	3/27/2018	1	20	0	8	12	0	12	100.00%
Pulmonary-Allergy Drugs Advisory Committee	7/25/2018	1	18	0	1	17	0	17	100.00%

Molecular and Clinical Genetics Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Neurological Devices Panel	9/27/2018	1	37	10	9	18	1	17	94.44%
Neurological Devices Panel	3/1/2018	1	33	4	14	15	0	15	100.00%
Obstetrics and Gynecology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Ophthalmic Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<u>Patient Engagement Advisory Committee</u>	<u>10/11-12/2017</u>	<u>1</u>	<u>9</u>	<u>0</u>	<u>0</u>	<u>9</u>	<u>0</u>	<u>9</u>	<u>100.00%</u>

Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants Not Issued Waivers
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH Cont.									
Orthopedic and Rehabilitation Devices Panel	12/12/2017	1	35	0	17	18	0	18	100.00%
TEPRSSC	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
National Mammography Quality Assurance Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Radiologic Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH		1	5	0 (0%)	0	5	0 (0%)	5	100.00%
Science Advisory Board to the National Center for Toxicological Research	11/6-7/2017	1	5	0	0	5	0	5	100.00%
CENTER FOR TOBACCO PRODUCTS		2	34 42	1	5 10	31	0	31	100.00%
Tobacco Products Scientific Advisory Committee	9/13-14/2018	1	16 20	1	5	16	0	16	100.00%
Tobacco Products Scientific Advisory Committee	1/24-25/2018	1	15 22	0	5	15	0	15	100.00%
* Not including Industry Representatives, Regular FDA Employees, and Guest Speakers									

FY 2019

Table 2 - 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted - FY 2019

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
FDA TOTALS	-----	48 49	1295 1250	48 50	334 330	811 870	7	863	99.14% 99.20%
OFFICE OF THE COMMISSIONER		4	119	1	25	93	0	93	100.00%
Science Board to the Food and Drug Administration	10/22/2018	1	16	0	1	15	0	15	100.00%
Pediatric Advisory Committee	4/8/2019	1	24	0	5	19	0	19	100.00%
Pediatric Advisory Committee	9/26/2019	1	40	1	11	28	0	28	100.00%
Pediatric Advisory Committee	9/27/2019	1	39	0	8	31	0	31	100.00%
CENTER FOR BIOLOGICS EVALUATION & RESEARCH		6	106	3	21	82	1	81	98.78%
Allergenic Products Advisory Committee	9/13/2019	1	11	3	0	8	0	8	100.00%
Blood Products Advisory Committee	3/20-21/2019	1	24	0	6	18	0	18	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
CENTER FOR BIOLOGICS EVALUATION & RESEARCH, CONTINUED...									
Vaccines and Related Biological Products Advisory Committee	10/3/2018	1	15	0	1	14	0	14	100.00%
Vaccines and Related Biological Products Advisory Committee	11/8/2018	1	13	0	4	9	0	9	100.00%
Vaccines and Related Biological Products Advisory Committee	3/6-7/2019	1	22	0	1	21	1	20	95.24%
Vaccines and Related Biological Products Advisory Committee	3/22/2019	1	21	0	9	12	0	12	100.00%
CENTER FOR DRUG EVALUATION & RESEARCH		28	754 <u>744</u>	25 <u>24</u>	180	542 <u>540</u>	6	538 <u>534</u>	98.99% <u>99.26%</u>
Anesthetic and Analgesic Drug Products Advisory Committee	10/11/18	1	14	0	1	13	0	13	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee	10/12/18	1	13	0	1	12	0	12	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee	11/14/18	1	36	0	19	17	0	17	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
CENTER FOR DRUG EVALUATION & RESEARCH, CONTINUED...									
Anesthetic and Analgesic Drug Products Advisory Committee	11/15/18	1	25	1	11	13	0	13	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting with DSARM.	12/17-18/2019	1	41	1	14	26	0	26	100.00%
Antimicrobial Drugs Advisory Committee	4/25/19	1	26	0	0	26	0	26	100.00%
Antimicrobial Drugs Advisory Committee	4/26/19	1	29	1	11	17	0	17	100.00%
Antimicrobial Drugs Advisory Committee	6/5/19	1	23	0	0	23	0	23	100.00%
Antimicrobial Drugs Advisory Committee	6/6/19	1	23	0	0	23	0	23	100.00%
Antimicrobial Drugs Advisory Committee	8/7/19	1	24	1	5	18	2	16	88.89%
Arthritis Advisory Committee	1/11/2019	1	28	4	2	22	1	21	95.45%
<u>Arthritis Advisory Committee</u>	<u>7/25/2019</u>	<u>1</u>	<u>23</u>	<u>1</u>	<u>5</u>	<u>17</u>	<u>0</u>	<u>17</u>	<u>100.00%</u>

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
CENTER FOR DRUG EVALUATION & RESEARCH, CONTINUED...									
Bone, Reproductive and Urologic Drugs Advisory Committee	1/16/2019	1	33	2	12	19	0	19	100.00%
Bone, Reproductive and Urologic Drugs Advisory Committee	1/16/2019	1	33	2	12	19	0	19	100.00%
Drug Safety and Risk Management Advisory Committee	6/11-12/2019	1	59	0	0	59	0	59	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	1/17/2019	1	17	0	2	15	0	15	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	10/24-25/2018	1	28	1	8	19	0	19	100.00%
Gastrointestinal Drugs Advisory Committee	10/18/2018	1	23	1	12	10	1	9	90.00%
Gastrointestinal Drugs Advisory Committee	10/17/2018	1	35	0	23	12	1	11	91.67%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
CENTER FOR DRUG EVALUATION & RESEARCH, CONTINUED...									
Nonprescription Drugs Advisory Committee	9/18/2019	1	21	0	0	21	0	21	100.00%
Oncologic Drugs Advisory Committee	5/14/19	1	29	0	0	29	0	29	100.00%
Oncologic Drugs Advisory Committee	10/10/2018	1	36	1	19	16	0	16	100.00%
Oncologic Drugs Advisory Committee	2/26/2019	1	23	6	3	14	0	14	100.00%
Pediatric Sub-Committee/ODAC	6/20/2019	1	16	2	4	10	1	9	90.00%
Pharmaceutical Science and Clinical Pharmacology Advisory Committee	5/7/19	1	20	1	5	14	0	14	100.00%
Psychopharmacologic Drugs Advisory Committee	11/1/18	1	24	0	1	23	0	23	100.00%
Psychopharmacologic Drugs Advisory Committee	11/2/18	1	21	0	3	18	0	18	100.00%
Psychopharmacologic Drugs Advisory Committee	2/12/19	1	29	1	10	18	0	18	100.00%
Pulmonary-Allergy Drugs Advisory Committee	5/8/19	1	25	0	9	16	0	16	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH		9	258	22	100	136	0	136	100.00%

Medical Devices Advisory Committee (Composed of 18 Panels)									
Circulatory System Devices Panel	12/4-5/2018	1	36	3	13	20	0	20	100.00%
Circulatory System Devices Panel	6/19-20/2019	1	37	4	17	16	0	16	100.00%
General and Plastic Surgery Devices Panel	3/25-26/2019	1	52	4	31	17	0	17	100.00%
General and Plastic Surgery Devices Panel	5/30-31/2019	1	33	0	23	10	0	10	100.00%
Microbiology Devices Panel	3/8/2019	1	23	1	5	17	0	17	100.00%
Neurological Devices Panel	3/21/2019	1	23	0	5	18	0	18	100.00%
Obstetrics and Gynecology Devices Panel	2/12-13/2019	1	28	10	5	13	0	13	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons Contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH, CONTINUED...									
Patient Engagement Advisory Committee	9/10/2019	1	13	0	1	12	0	12	100.00%
Patient Engagement Advisory Committee	11/15/2018	1	13	0	0	13	0	13	100.00%
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH		1	9	0	4	5	0	5	100.00%
Science Advisory Board to the National Center for Toxicological Research	3/19/2019	1	9	0	4	5	0	5	100.00%
CENTER FOR TOBACCO PRODUCTS		1	14	0	0	14	0	14	100.00%
Tobacco Products Scientific Advisory Committee	2/6-7/2019	1	14	0	0	14	0	14	100.00%
* Not including Industry Representatives, Regular FDA Employees, and Guest Speakers									

FY 2020

Table 2 - 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted - FY 2020

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants With No Waivers	% of Meeting Participants <u>Not Issued</u> Waivers
FDA TOTALS	-----	34 30	757 646	31 29	193 162	532 455	9	523 446	98.31% 98.02%
OFFICE OF THE COMMISSIONER		2	39	0	0 1	38	1	37	97.37%
Science Board to the Food and Drug Administration	10/7/2019	1	15	0	0 1	14	0	14	100.00%
Pediatric Advisory Committee	9/15/2020	1	24	0	0	24	1	23	95.83%
CENTER FOR BIOLOGICS EVALUATION & RESEARCH		5	74	4	16	54	0	54	100.00%
Allergenic Products Advisory Committee	11/22/2019	1	15	2	2	11	0	11	100.00%
Blood Products Advisory Committee	5/8/2020	1	15	0	1	14	0	14	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants With No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
CENTER FOR BIOLOGICS EVALUATION & RESEARCH, CONTIUNED...									
Vaccines and Related Biological Products Advisory Committee	10/9/2019	1	16	0	7	9	0	9	100.00%
Vaccines and Related Biological Products Advisory Committee	11/8/2019	1	14	2	4	8	0	8	100.00%
Vaccines and Related Biological Products Advisory Committee	3/4/2020	1	14	0	2	12	0	12	100.00%
CENTER FOR DRUG EVALUATION & RESEARCH		<u>21</u> <u>17</u>	<u>513</u> <u>402</u>	<u>20</u> <u>18</u>	<u>145</u> <u>113</u>	<u>348</u> <u>271</u>	6	<u>342</u> <u>265</u>	<u>98.28%</u> <u>97.79%</u>
Anesthetic and Analgesic Drug Products Advisory Committee	1/16/20	1	15	1	2	12	0	12	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting with DSARMAC	1/14/20	1	45	0	18	27	0	27	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting with DSARMAC	1/15/20	1	40	0	14	26	0	26	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants With No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
CENTER FOR DRUG EVALUATION & RESEARCH, CONTINUED...									
Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting with DSARMAC	1/15/20	1	41	0	15	26	0	26	100.00%
DSARM with Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting	1/15/20	1	35	1	6	28	0	28	100.00%
Antimicrobial Drugs Advisory Committee	10/16/19	1	25	0	9	16	0	16	100.00%
Bone, Reproductive, and Urologic Drugs Advisory Committee	10/29/2019	1	29	2	11	16	0	16	100.00%
Bone, Reproductive, and Urologic Drugs Advisory Committee	10/30/2019	1	32	3	12	17	1	16	94.12%
Cardiovascular and Renal Drugs Advisory Committee	7/15/2020	1	17	1	1	15	0	15	100.00%
Cardiovascular and Renal Drugs Advisory Committee	12/10/2019	1	17	1	2	14	0	14	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	11/13/2019	1	16	0	0	16	0	16	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants With No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
CENTER FOR DRUG EVALUATION & RESEARCH, CONTINUED...									
Endocrinologic and Metabolic Drugs Advisory Committee	11/14/2019	1	20	0	4	16	0	16	100.00%
Oncologic Drugs Advisory Committee	12/17/2020	1	14	0	2	12	0	12	100.00%
Oncologic Drugs Advisory Committee	12/17/ 2020 <u>2019</u>	1	19	2	3	14	0	14	100.00%
Oncologic Drugs Advisory Committee	12/18/ 2020 <u>2019</u>	1	17	3	3	11	0	11	100.00%
Oncologic Drugs Advisory Committee	2/26/20	1	26	2	9	15	0	15	100.00%
Oncologic Drugs Advisory Committee	2/26/20	1	21	1	9	11	0	11	100.00%
Oncologic Drugs Advisory Committee	7/14/2020	1	21	2	5	14	0	14	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants With No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH		2	18	0	0	18	0	18	100.00%
Science Advisory Board to the National Center for Toxicological Research	8/18-19/2020	1	9	0	0	9	0	9	100.00%
Science Advisory Board to the National Center for Toxicological Research	12/3-4/2019	1	9	0	0	9	0	9	100.00%
CENTER FOR TOBACCO PRODUCTS		1	14	0	0	14	0	14	100.00%
Tobacco Products Scientific Advisory Committee	2/14/2020	1	14	0	0	14	0	14	100.00%

* Not including Industry Representatives, Regular FDA Employees, and Guest Speakers

FY 2021

Table 2 – FY 2021’s Section 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not Issued</u> Waivers
FDA’s Totals	-----	37	336 890	61 73	121 160	654 657	26	632 631	96.64% 96.04%
Center for Biologics Evaluation & Research		11	270	18	34	218	11	207	94.95%
Cellular, Tissue and Gene Therapies Advisory Committee	4/15/2021	1	19	1	2	16	0	16	100.00%
Cellular, Tissue and Gene Therapies Advisory Committee	9/2-3/2021	1	25	2	1	22	4	18	81.82%
Vaccines and Related Biological Products Advisory Committee	10/2/2020	1	15	0	0	15	0	15	100.00%
Vaccines and Related Biological Products Advisory Committee	10/22/2020	1	29	6	1	22	2	20	90.91%
Vaccines and Related Biological Products Advisory Committee	12/10/2020	1	35	0	8	27	1	26	96.30%
Vaccines and Related Biological Products Advisory Committee	12/17/2020	1	34	0	7	27	1	26	96.30%
Vaccines and Related Biological Products Advisory Committee	2/26/2021	1	27	0	7	20	1	19	95.00%
Vaccines and Related Biological Products Advisory Committee	3/5/2021	1	16	0	0	16	0	16	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not Issued</u> Waivers
Vaccines and Related Biological Products Advisory Committee	6/10/2021	1	26	0	6	20	1	19	95.00%
Vaccines and Related Biological Products Advisory Committee	9/17/2021	1	28	9	1	18	1	17	94.00%
Vaccines and Related Biological Products Advisory Committee	9/30/2021	1	16	0	1	15	0	15	100.00%
Center for Devices & Radiological Health		9	237	21	56 <u>57</u>	159	2 <u>1</u>	157 <u>158</u>	98.74%
Medical Devices Advisory Committee									
Circulatory System Devices Panel	10/27/2021	1	25	0	5	20	0	20	100.00%
Circulatory System Devices Panel	2/17/2021	1	32	3	8	21	0	21	100.00%
Circulatory System Devices Panel	4/6/2021	1	26	2	2	22	0	22	100.00%
Circulatory System Devices Panel	8/3/2021	1	28	2	6	20	0	20	100.00%
Gastroenterology and Urology Devices Panel	7/14/2021	1	45	13	15	17	1	16	94.12%
General and Plastic Surgery Devices Panel	3/23/2021	1	22	0	9	13	0	13	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not Issued</u> Waivers
Neurological Devices Panel	6/3-4/2021	1	20	0	3	17	0	17	100.00%
Ophthalmic Devices Panel	11/9/2020	1	28	1	8	19	0	19	100.00%
Patient Engagement Advisory Committee	10/22/2020	1	11	0	1	10	0	10	100.00%
Center for Drug Evaluation & Research		15	356	34	67	255	14	241	94.51%
Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting With DSaRM	11/2/2020	1	27	4	2	21	0	21	100.00%
Arthritis Advisory Committee Joint Meeting With DSaRM	3/24-25/2021	1	36	3	13	20	0	20	100.00%
Arthritis Advisory Committee	5/6/2021	1	22	0	4	18	1	17	94.44%
Cardiovascular and Renal Drugs Advisory Committee	12/15/2020	1	15	1	1	13	0	13	100.00%
Cardiovascular and Renal Drugs Advisory Committee	12/16/2020	1	15	1	1	13	0	13	100.00%
Cardiovascular and Renal Drugs Advisory Committee	7/15/2021	1	20	1	5	14	1	13	92.86%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not Issued</u> Waivers
Endocrinologic and Metabolic Drugs Advisory Committee	5/27/2021	1	21	0	4	17	0	17	100.00%
Oncologic Drugs Advisory Committee	2/9/2021	1	22	9	3	10	4	6	60.00%
Oncologic Drugs Advisory Committee	4/27-29/2021	1	44	11	12	21	6	15	71.43%
Oncologic Drugs Advisory Committee	6/24/2021	1	20	2	1	17	0	17	100.00%
Pediatric Sub-Committee of the Oncologic Drugs Advisory Committee	5/11-12/2021	1	21	1	2	18	0	18	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	11/6/2020	1	14	0	3	11	0	11	100.00%
Pharmacy Compounding Advisory Committee	6/9/2021	1	17	0	0	17	2	15	88.24%
Psychopharmacologic Drugs Advisory Committee/Drug Safety and Risk Management	10/8/2020	1	34	0	11	23	0	23	100.00%
Psychopharmacologic Drugs Advisory Committee/Drug Safety and Risk Management	10/9/2020	1	28	1	5	22	0	22	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not Issued</u> Waivers
National Center for Toxicological Research		1	8	0	0	8	0	8	100.00%
Science Advisory Board to the National Center for Toxicological Research	5/11-12/2021	1	8	0	0	8	0	8	100.00%
Office of the Commissioner		1	19	0	2	17	0	17	100.00%
Pediatric Advisory Committee	9/17/2021	1	19	0	2	17	0	17	100.00%
* Not including industry representatives, FDA employees, and guest speakers									

FY 2022

Table 2 – FY 2022’s Section 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons contacted and Not Serving due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
FDA TOTALS	-----	35	819	54	193	572	22	550	96.15%
Office of the Commissioner		1	13	1	0	12	0	12	100.00%
Science Board to the Food and Drug Administration	6/14/2022	1	13	1	0	12	0	12	100.00%
Center for Biologics Evaluation & Research		13	306	30	36	240	5	235	97.92%
Allergenic Products Advisory Committee	10/28/2021	1	16	0	0	16	0	16	100.00%
Blood Products Advisory Committee	11/4/2021	1	19	0	4	15	0	15	100.00%
Cellular, Tissue and Gene Therapies Advisory Committee	3/10/2022	1	13	0	2	11	0	11	100.00%
Cellular, Tissue and Gene Therapies Advisory Committee	6/9-10/2022	1	26	2	4	20	0	20	100.00%
Cellular, Tissue and Gene Therapies Advisory Committee	6/29-30/2022	1	23	0	5	18	0	18	100.00%
Vaccines and Related Biological Products Advisory Committee	10/14-15/2021	1	28	6	2	20	1	19	95.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons contacted and Not Serving due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants Not Issued Waivers
Vaccines and Related Biological Products Advisory Committee	10/26/2021	1	28	6	2	20	1	19	95.00%
Vaccines and Related Biological Products Advisory Committee	3/3/2022	1	19	0	5	14	0	14	100.00%
Vaccines and Related Biological Products Advisory Committee	4/6/2022	1	28	4	4	20	1	19	95.00%
Vaccines and Related Biological Products Advisory Committee	6/7/2022	1	28	5	1	22	0	22	100.00%
Vaccines and Related Biological Products Advisory Committee	6/14-15/2022	1	28	4	0	24	1	23	95.83%
Vaccines and Related Biological Products Advisory Committee	6/28/2022	1	30	3	5	22	1	21	95.45%
Vaccines and Related Biological Products Advisory Committee	9/22/2022	1	20	0	2	18	0	18	100.00%
Center for Drug Evaluation & Research		13	330	12	107	211	10	201	95.26%
Antimicrobial Drugs Advisory Committee	10/7/2021	1	24	5	2	17	0	17	100.00%
Antimicrobial Drugs Advisory Committee	11/30/2021	1	29	1	5	23	0	23	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons contacted and Not Serving due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
Cardiovascular and Renal Drugs Advisory Committee	12/8/2021	1	20	0	7	13	0	13	100.00%
Anesthetic and Analgesic Drug Advisory Committee/Drug Safety and Risk Management Advisory Committee (joint meeting)	2/15/2022	1	25	1	2	22	0	22	100.00%
Oncologic Drugs Advisory Committee	2/10/2022	1	20 25	1	9	15	2	13	86.67%
Oncologic Drugs Advisory Committee	4/21-22/2022	1	26	0	9	17	0	17	100.00%
Oncologic Drugs Advisory Committee	9/22-23/2022	1	39	2	14	23	5	18	78.26%
Pediatric Sub-Committee of the Oncologic Drugs Advisory Committee	5/11-12/2022	1	19	0	3	16	0	16	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	3/30/2022	1	18	0	8	10	0	10	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	9/7/2022	1	11	0	2	9	0	9	100.00%
Pharmacy Compounding Advisory Committee	6/8/2022	1	49	1	27	21	2	19	90.48%
Psychopharmacologic Drugs Advisory Committee	11/4/2021	1	21	0	8	13	0	13	100.00%
Psychopharmacologic Drugs Advisory Committee	6/17/2022	1	24	1	11	12	1	11	91.67%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons contacted and Not Serving due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants Not Issued Waivers
Center for Devices & Radiological Health		7	161	11	50	100	7	93	93.00%
Device Good Manufacturing Practice Advisory Committee	3/2/2022	1	7	0	0	7	0	7	100.00%
Circulatory System Devices Panel	11/2-3/2021	1	28	6	3	19	5	14	73.68%
General and Plastic Surgery Devices Panel	10/20/2021	1	30	1	14	15	0	15	100.00%
General and Plastic Surgery Devices Panel	7/28-29/2022	1	44	2	24	18	0	18	100.00%
Neurological Devices Panel	12/10/2021	1	23	2	5	16	0	16	100.00%
Patient Engagement Advisory Committee	10/6/2021	1	12	0	1	11	1	10	90.91%
Patient Engagement Advisory Committee	7/12-13/2022	1	17	0	3	14	1	13	92.86%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
National Center for Toxicological Research		1	9	0	0	9	0	9	100.00%
Science Advisory Board to the National Center for Toxicological Research	5/18-19/2022	1	9	0	0	9	0	9	100.00%
Center for Tobacco Products		0	0	0	0	0	0	0	0
Tobacco Products Scientific Advisory Committee									
* Not including Industry Representatives, Regular FDA Employees, and Guest Speakers									

FY2023

Table 2 – FY 2023’s Section 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
FDA’s TOTALS	-----	53	1340	73	441 <u>439</u>	826 <u>828</u>	23	803 <u>804</u>	97.22% <u>97.10%</u>
Office of the Commissioner		4 <u>2</u>	13 <u>45</u>	1 <u>0</u>	9 <u>7</u>	12 <u>38</u>	0	12 <u>38</u>	100.00%
Science Board to the Food and Drug Administration	12/8/2022	1	12	0	0	12	0	12	100.00%
Pediatric Advisory Committee	9/19/2023	1	33	0	7	26	0	26	100.00%
Center for Biologics Evaluation and Research		10	242	27	54	161	3	158	98.14%
Cellular, Tissue, and Gene Therapies Advisory Committee	5/12/2023	1	32	6	11	15	0	15	100.00%
Cellular, Tissue, and Gene Therapies Advisory Committee	9/27/2023	1	48	6	22	20	1	19	95.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
Blood Products	12/8/2022	1	18	0	3	15	0	15	100.00%
Blood Products	4/26/2023	1	18	0	3	15	0	15	100.00%
Vaccines and Related Biological Products	10/6/2022	1	17	1	1	15	0	15	100.00%
Vaccines and Related Biological Products	1/26/2023	1	25	4	3	18	1	17	94.44%
Vaccines and Related Biological Products	2/28-3/1/2023	1	20	2	4	14	0	14	100.00%
Vaccines and Related Biological Products	3/7/2023	1	15	0	3	12	0	12	100.00%
Vaccines and Related Biological Products	5/18/2023	1	22	4	3	15	0	15	100.00%
Vaccines and Related Biological Products	6/15/2023	1	27	4	1	22	1	21	95.45%
Vaccines and Related Biological Products	1/26/2023	4	25	4	3	18	1	17	94.44%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
Center for Drug Evaluation and Research		31	748	24	<u>244</u> <u>242</u>	<u>480</u> <u>482</u>	<u>11</u> <u>12</u>	<u>469</u> <u>470</u>	<u>97.71%</u> <u>97.51%</u>
Anesthetic and Analgesic Drug Products Advisory Committee	4/19/2023	1	16	0	3	13	0	13	100.00%
Obstetrics, Reproductive, and Urologic Drugs Advisory Committee	10/17-19/2022	1	34	0	18	16	0	16	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee	4/19/2023	1	16	0	3	13	0	13	100.00%
Obstetrics, Reproductive, and Urologic Drugs Advisory Committee	10/17-19/2022	1	34	0	18	16	0	16	100.00%
Antimicrobial Drugs Advisory Committee	4/17/2023	1	14	0	1	13	0	13	100.00%
Antimicrobial Drugs Advisory Committee	3/16/2023	1	24	2	4	18	2	16	88.89%
Antimicrobial Drugs Advisory Committee	6/8/2023	1	26	0	4	22	2	20	90.91%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
Antimicrobial Drugs Advisory Committee	1/24/2023	1	19	1	2	16	0	16	100.00%
Cardiovascular and Renal Drugs Advisory Committee	10/26/2022	1	27	1	9	17	0	17	100.00%
Cardiovascular and Renal Drugs Advisory Committee	11/16/2022	1	18	1	3	14	0	14	100.00%
Cardiovascular and Renal Drugs Advisory Committee	12/13/2022	1	17	0	5	12	0	12	100.00%
Cardiovascular and Renal Drugs Advisory Committee	9/13/2023	1	17	0	4	13	0	13	100.00%
Dermatologic and Ophthalmic Drugs Advisory Committee	1/9/2023	1	15	2	5	8	0	8	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	6/28/2023	1	22	0	7	15	0	15	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	9/21/2023	1	32	1	11	20	0	20	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
Gastrointestinal Drugs Advisory Committee	5/19/2023	1	25	1	7	17	3	14	82.35%
Joint meeting- Drug Safety and Risk Management Advisory Committee and the Ophthalmic Drugs Advisory Committee	3/28-29/2023	1	38	0	15	23	0	23	100.00%
Joint Meeting- Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee	2/15/2023	1	28	1	6	21	0	21	100.00%
Joint Meeting- Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee	5/9-10/2023	1	28	0	9	19	0	19	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
Joint Meeting- Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee	4/14/2023	1	18	2	5	11	1	10	90.91%
Medical Imaging Drugs Advisory Committee	8/1/2023	1	16	0	1	15	0	15	100.00%
Nonprescription Drugs Advisory Committee	9/11-12/2023	1	38	0	21	17	0	17	100.00%
Oncologic Drugs Advisory Committee	10/28/2022	1	38	1	20	17	0	17	100.00%
Oncologic Drugs Advisory Committee	2/9/2023	1	22	0	8	14	1	13	92.86%
Oncologic Drugs Advisory Committee	3/9/2023	1	28	0	14	14	0	14	100.00%
Oncologic Drugs Advisory Committee	4/28/2023	1	27	1	12	14	0	14	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee	6/16/2023	1	17	0	3	14	0	14	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	3/22/2023	1	15	1	4	10	1	9	90.00%
Peripheral and Central Nervous System Drugs Advisory Committee	6/9/2023	1	18	3	8	7	4 <u>2</u>	6 <u>5</u>	85.71% <u>71.43%</u>
Pharmaceutical Science and Clinical Pharmacology Advisory Committee	11/2-3/2022	1	21	1	4 <u>3</u>	17	0	17	100.00%
Pulmonary-Allergy Drugs Advisory Committee	11/8/2022	1	31	2	12 <u>11</u>	18	0	18	100.00%
Pulmonary-Allergy Drugs Advisory Committee	11/9/2022	1	23	2	7	14	0	14	100.00%
Pulmonary-Allergy Drugs Advisory Committee	5/11/2023	1	36	1	12	23	0	23	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
Center for Devices and Radiological Health		8	287	22	136	129	9	120	93.02%
Anesthesiology Devices Panel	11/1/2022	1	29	0	12	17	1	16	94.12%
Circulatory System Devices Panel	8/22-23/2023	1	41	14	10	17	4	13	76.47%
Clinical Chemistry and Clinical Toxicology Devices Panel	10/20/2022	1	40	2	22	16	0	16	100.00%
General and Plastic Surgery Devices Panel	10/26-27/2023	1	62	2	35	25	1	24	96.00%
Microbiology Devices Panel	9/7-8/2023	1	39	3	20	16	1	15	93.75%
Ophthalmic Devices Panel	11/10/2022	1	18	1	5	12	0	12	100.00%
Orthopedic and Rehabilitation Devices Panel	4/20/2023	1	42	0	30	12	0	12	100.00%
Patient Engagement Advisory Committee	9/6/2023	1	16	0	2	14	2	12	85.71%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
National Center for Toxicological Research		1	9	0	0	9	0	9	100.00%
Science Advisory Board to the National Center for Toxicological Research	4/4-5/2023	1	9	0	0	9	0	9	100.00%
Center for Tobacco Products		1	9	0	0	9	0	9	100.00%
Tobacco Products Scientific Advisory Committee	5/18/2023	1	9	0	0	9	0	9	100.00%